Skip to main content

Table 5 Demographic characteristics of all studied subjects and statistical comparison between EHCC and AHCCa using Wilcoxon’s rank-sum test and between all the studied groups using Kruskal-Wallis testb

From: CTNNB1 polymorphism (rs121913407) in circulating tumor DNA (ctDNA) in Egyptian hepatocellular carcinoma patients

Parameters

EHCC patients (n = 12)

AHCC patients (n = 16)

p-value

HCV patients (n = 10)

Healthy control (n = 10)

p-value

Age (years)

60 (55–63)

57 (52–60)

0.193a

64 (60–69)

60 (56–62)

0.0509b

Albumin (g/dl)

3.6 (3.2–3.6)

2.9 (2.5–3.4)

0.0013a

3.9 (3.3–4.7)

3.9 (3.2–4.6)

0.0037b

Total bilirubin (mg/dl)

1.15 (0.9–1.9)

1.4 (0.8–4.3)

0.0105a

0.5 (0.3–0.9)

0.4 (0.2–0.9)

< 0.0001b

INR

1.15 (1.1–1.2)

1.39 (1.2–1.65)

0.1635a

1.05 (1–1.29)

0.85 (0.62–1.1)

0.0002b

BUN (mg/dl)

12 (10–18)

13 (10–26)

0.0298a

20 (17–24)

17 (9–20)

0.0012b

Creatinine (mg/dl)

0.75 (0.63–1)

1.05 (0.9–1.63)

0.0173a

0.95 (0.8–1.1)

0.9 (0.7–1)

0.0344b

AST (U/L)

40 (33–47)

93 (59–190)

0.2746a

24 (19–35)

13 (12–18)

< 0.0001b

ALT (U/L)

40 (31–50)

66 (32–95)

0.0029a

24 (12–52)

17 (12–21)

0.0006b

AFP (ng/ml)

5.5 (3.3–136)

250 (65–9784)

0.0117a

4.6 (3.1–6.1)

3.6 (2.5–4.6)

< 0.0001b

  1. AHCC advanced hepatocellular carcinoma, ALT alanine aminotransferase, AST aspartate aminotransferase, BUN blood urea nitrogen, EHCC early hepatocellular carcinoma, HCC hepatocellular carcinoma, HCV hepatitis C, INR international normalized ratio. Data are presented as median (interquartile range).. < 0.05 is significant
  2. aStatistical comparison between EHCC and AHCC using Wilcoxon’s rank-sum test
  3. bStatistical comparison between all groups using Kruskal-Wallis test